Targeting IRAK4 in chronic lymphocytic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug that targets a protein called IRAK4, which may help treat chronic lymphocytic leukemia (CLL). It is for adults with CLL who are willing to join the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a diagnosis of chronic lymphocytic leukemia (CLL).
- You must be willing and able to give informed consent to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
This trial tests two oral targeted drugs (BGB-16673 and sonrotoclax) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not had treatment before. The goal is to see if this combination is safe and effective.
This study looks at how well BTK inhibitors work in people with chronic lymphocytic leukemia (CLL) in real-world settings. It includes both new patients and those who have had treatment before.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.